Please login to the form below

Not currently logged in
Email:
Password:

Tagrisso

This page shows the latest Tagrisso news and features for those working in and with pharma, biotech and healthcare.

Chi-Med goes for third IPO in Hong Kong

Chi-Med goes for third IPO in Hong Kong

combination with the latter’s EGFR inhibitor Tagrisso (osimertinib) and PD-L1 checkpoint inhibitor Imfinzi (durvalumab) in a series of proof-of-concept trials in solid tumours.

Latest news

More from news
Approximately 24 fully matching, plus 34 partially matching documents found.

Latest Intelligence

  • AstraZeneca’s oncology renaissance AstraZeneca’s oncology renaissance

    Eight years on, three new oncology drugs are proving to be the driving force for the new AstraZeneca: small molecule, targeted lung cancer drug Tagrisso (osimertinib) and ovarian cancer treatment Lynparza ... EvaluatePharma forecasts that Lynparza (now co

  • China: AstraZeneca’s new engine for growth and innovation China: AstraZeneca’s new engine for growth and innovation

    In March 2017, AZ’s targeted lung cancer drug Tagrisso was one of the first medicines to gain approval through the Chinese Food and Drug Administration (CFDA)’s Priority Review pathway, ... Liang had been instrumental in building up the company’s

  • Biopharma's Future: Made in China Biopharma's Future: Made in China

    targeted lung cancer drug Tagrisso and diabetes treatment Forxiga.

  • 30 Women Leaders in UK Healthcare 30 Women Leaders in UK Healthcare

    She played a key role in the development and approval of Tagrisso, AstraZeneca’s next-generation EGFR-targeting lung cancer treatment that is proving a major advance on existing treatments, and

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Star

We're passionate about helping our clients to make a real commercial impact. We achieve this through our unique approach to...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics